Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Recall of sex enhancement drug

This article was originally published in The Tan Sheet

Executive Summary

Century City, Calif.-based Bodee LLC has initiated a voluntary nationwide recall of "natural" male sexual enhancement drug Zencore Tabs after FDA analysis revealed the product contains "potentially harmful, undeclared ingredients," agency reports Aug. 31. Lots of the product contained aminotadalafil or sildenafil, ingredients in FDA-approved drugs used for erectile dysfunction. The chemicals pose a threat because they may interact with nitrates found in some prescription drugs. Zencore Tabs are sold in health food stores and by mail order in the U.S. and Canada. Canadian health authorities have issued warnings since April about sexual enhancement drugs laced with unapproved ingredients, and the Center for Science in Public Interest recently sent a letter to FDA urging a ban on U.S. sales of Zencore Tabs and Vitogen's Axcil brand(1"The Tan Sheet" Aug. 27, 2007, p. 10)...

You may also be interested in...

CSPI Urges Recalls Of Zencore, Axcil Pending Ingredient, Ad Claims Reviews

The Zencore Tabs and Axcil sexual enhancementsupplements are adulterated and "deceptively labeled" and should be banned from sales in the U.S., according to the Center for Science in Public Interest

The Cost Of Coronavirus: Medtech Market Wins And Losses

With the rapid global spread of the coronavirus, Medtech Insight looks at the predicted economic impact of the outbreak on the industry’s biggest businesses.

Yes For Shionogi But No For Lilly In Latest EMA Recommendations

The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts